Microbot Medical Secures Chinese Patent for Robotic System

Microbot Medical ( (MBOT) ) just unveiled an update.

On June 17, 2025, Microbot Medical announced it was granted a patent in China for the robotic manipulation of a surgical tool handle, marking a significant step in its global intellectual property expansion strategy. This development supports the company’s long-term commercial strategy for the LIBERTY Endovascular Robotic System, which is anticipated to launch in the U.S. market in Q3 2025 upon FDA clearance. The patent strengthens Microbot’s competitive edge and positions it to expand into international markets, with a focus on enhancing procedural capabilities and improving patient outcomes worldwide.

The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, targeting the elimination of traditional barriers to advanced robotic systems.

Average Trading Volume: 2,598,422

Technical Sentiment Signal: Buy

Current Market Cap: $89.13M

For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.